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Abstract
Background: Idiopathic pulmonary fibrosis represents a lethal form of progressive fibrotic lung disorder with
gradually increasing incidence worldwide. Despite intense research efforts its pathogenesis is still elusive and
controversial reflecting in the current disappointing status regarding its treatment. Patients and Methods: We report
the first protocol proposal of a prospective, unicentric, non-randomized, phase Ib clinical trial to study the safety
and tolerability of the adipose-derived stem cells (ADSCs) stromal vascular fraction (SVF) as a therapeutic agent in
IPF. After careful patient selection based on functional criteria (forced vital capacity-FVC > 50%, diffuse lung
capacity for carbon monoxide-DLCO > 35% of the predicted values) all eligible subjects will be subjected to
lipoaspiration resulting in the isolation of approximately 100- 500 gr of adipose tissue. After preparation, isolation
and labelling ADSCs-SVF will be endobronchially infused to both lower lobes of the fibrotic lungs. Procedure will
be repeated thrice at monthly intervals. Primary end-point represent safety and tolerability data, while exploratory
secondary end-points include assessment of clinical functional and radiological status. Results: Preliminary results
recently presented in the form of an abstract seem promising and tantalizing since there were no cases of
clinically significant allergic reactions, infections, disease acute exacerbations or ectopic tissue formation. In addition
6 months follow-up data revealed a marginal improvement at 6-minute walking distance and forced vital capacity.
Conclusions: Adipose tissue represents an abundant, safe, ethically uncontested and potentially beneficial source
of stem cells for patients with IPF. Larger multicenter phase II and III placebo-controlled clinical trials are sorely
needed in order to prove efficacy. However, pilot safety studies are of major importance and represent the first
hamper that should be overcome to establish a rigid basis for larger clinical trials.
Keywords: stem cells, adipose tissue, stromal vascular fraction, idiopathic pulmonary fibrosis, therapy, endobron-
chial infusion, prospective, nonrandomized phase Ib clinical trial
Background
IPF is a refractory and lethal form of pulmonary fibrosis
characterized by fibroblast proliferation, extracellular
matrix deposition, and progressive lung scarring, and
comprises the histopathologic pattern of usual intersti-
tial pneumonia (UIP). The incidence of IPF is estimated
at 6.8 to 16.3 cases per 100, 000 per year in the United
States, and the mean survival from the time of diagnosis
is 3 to 5 years regardless of treatment, showing a prog-
nosis worst that than seen in patients lung cancer [1-3].
Although the etiology and pathogenesis of IPF remain
poorly understood, current research suggests that the
mechanisms driving IPF reflect abnormal, deregulated
wound healing in response to multiple sites of ongoing
alveolar epithelial injury, involving increased activity and
possibly exaggerated responses by a spectrum of proin-
flammatory and profibrogenic factors [4-10]. So far,
despite intense research efforts and clinical trials, there
is still no effective treatment that can prolong the survi-
val of patients with IPF [11-14]. Conventional therapeu-
tic approach includes combination of corticosteroids,
anti-oxidants, immunosuppressants and immunomodu-
latory anti-fibrotic agents [11-16]. However, the only, so
far, therapeutic approach that has been proven effective
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plantation. Nonetheless, not all the patients with IPF are
eligible for lung transplantation whereas there is a sig-
nificant proportion of these patients that finally suc-
cumb while waiting in a lung transplantation list.
Therefore, there is critical need for more effective and
reliable therapeutic modalities.
Mesenchymal stem cells (MSCs), of different cellular
origins (umbilical cord, bone marrow, adipose tissue),
represent one of the most challenging and promising
areas of novel therapeutic strategies that have been
recently applied apart from cosmetic reasons, in several
chronic, incurable, fatal diseases such as diabetes mellitus
type II, Parkinson’s disease, congestive heart failure, renal
failure, osteoarthritis and myocardial infarction [17-23].
Of special interest are adipose-derived stem cells
(ADSCs)- stromal vascular fraction (SVF), as they pre-
sent with fruitful therapeutic advantages against bone
marrow stem cells including ease of extraction, higher
content of MSCs and ex-vivo expandability [21,22]. Cur-
rently we have witnessed an explosion of experimental
data supporting the migratory, differentiative and
reparative capacity of MSCs in animal models of lung
inflammation and fibrosis [21,22]. In particular, a num-
ber of studies have investigated the role of umbilical
cord MSCs as a treatment option in the experimental
model of pulmonary fibrosis and showed their potency
to be differentiated under a specific micro-environment,
into alveolar type II epithelial cells [24] whereas mice
adult-stem cells can attenuatel u n gf i b r o s i si nt h eb l e o -
mycin-model of pulmonary fibrosis [25,26]. Further-
more, repeated intravenous administrations of human
and mouse ADSCs resulted in substantial beneficial
effects in a model of inflammation and injury induced
by cigarette-smoke exposure [27]. More intriguingly a
recent report demonstrated for the first time rigid evi-
dence supporting the presence of resident stem cells
within human lungs that exert beneficial role in tissue
homeostasis and regeneration in animal models [28].
Despite promising therapeutic results arising from
experimental studies safety issues and concerns coupled
with major controversies regarding IPF pathogenesis,
have severely hampered chest physicians’ efforts to
apply cell-based therapies for the treatment of this dis-
mal disease. To address the above concerns and to
establish a rigid basis for future efficacy trials, we are
reporting the first protocol proposal of a nonrando-
mized, unicentric, dose-ranging phase Ib safety study of
endobronchial infusion of autologous ADSCs-SVF in
IPF patients with moderate disease severity.
Aim and hypothesis
The aim of the study is to investigate the hypothesis that
endobronchial autologous infusion of ADSCs-SVF cells is
safe, feasible and well tolerated as a therapeutic modality
in IPF patients. Our main hypothesis is that the above
procedure can provide to the targeted areas of epithelial
injury and excessive fibrotic tissue with adequate number
of minimally manipulated multi-potent SVF cells with
increased anti-inflammatory paracrine activity as well as
regenerative capacity overcoming the fear and concern of
undesirable alterations of MSCs during ex-vivo cellular
expansion, including contaminations, tumor, ectopic tis-
sue formation and lung toxicity resulting from undesir-
able engraftment in the microvasculature.
Patients and methods
In our phase Ib dose escalating study will participate 12
with IPF, respectively, based on the recently published
diagnostic criteria of ATS/ERS (2011), of mild to mod-
erate disease severity as estimated functional parameters
including forced vital capacity (FVC) > 50% and diffus-
ing lung capacity for carbon monoxide (DLCO) > 35% of
the predicted normal values. All patients will sign an
informed consent form where they will agree to their
participation in the study and the anonymous usage of
their biological fluids for research purposes (see inclu-
sion criteria below).
Inclusion criteria
Patients with a histologic or radiologic pattern typical of
usual interstitial pneumonia will be included after other
causes of fibrosis are ruled out.
The inclusion criteria are:
1. Age 18 to 75 years (both inclusive),
2. A high-resolution computed tomography (HRCT)
scan that is very suggestive or consistent with a
probable diagnosis of usual interstitial pneumonia.
3. Bronchoalveolar lavage must be performed at any
time before inclusion and must have failed to show
features supporting alternative diagnoses.
4. The duration of the disease should be more than
three months, and bibasilar inspiratory crackles
should be present. In addition, the following func-
tional abnormalities have to be present: a dyspnea
score of at least 2 on a scale of 0 (minimum) to 10
(maximum), FVC > 50% of the predicted normal
value and DLco > 35% of the predicted value.
5. Patients willing to sign an informed consent form
where they will agree to their participation in the
study and the anonymous usage of their biological
fluids for research purposes according to the
Declaration of Helsinki.
6. Patients under treatment with n-acetylcysteine or
pirfenidone should discontinue drug and enter a
wash-out period for at least 6 weeks prior study
enrolment.
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1. IPF patients of severe disease based on the base-
line functional data, meaning those with FVC < 50%
predicted normal value and DLCO < 35%predicted
normal value.
2. Patients diagnosed with lung cancer or with an
evidence of active malignancy, or prior history of
active malignancy that has not been in remission for
at least 5 years
3. Patients with documented history of uncontrolled
heart, renal or hepatic failure,
4. Patients with serious neurological abnormalities
including stroke and myasthenia Gravis
5. Patients under anti-coagulants or in serious
emaciation.
6. Patients with active infections.
7. Patients unable to be regularly followed up includ-
ing those with serious psychiatric disorders.
8. Patients unwilling to sign informed consent form
Study Methodology
1) Approval by Local Ethics and Scientific Commit-
tee: Original protocol has already been approved by the
Local Ethics and Scientific Committee of the University
Hospital of Alexandroupolis, Democritus University of
Thrace, Greece (reference number EHD33/1SC/16-02-
2010)
2) Inform consent: Patients willing to sign an
informed consent form where they will agree to their
participation in the study and the anonymous usage of
their biological fluids for research purposes according to
the Declaration of Helsinki.
3) Physical and laboratory examination: All patients
will undergo a detailed physical and laboratory examina-
tion including: arterial blood gases, electrocardiogram
(ECG), estimation of vital signs (blood pressure, tem-
perature, breaths and beats per minute) as well as rou-
tine laboratory tests, including white blood cell count
and differential count, red blood cell count, liver and
renal function, serum C-reactive protein. Patients will
undergo spirometry and chest HRCT, at screening to
evaluate the functional and radiological severity of the
disease and to localize the areas of the lungs where the
infusion of SVF cells will be targeted to (Figure 1).
4) Lipoaspiration and isolation of ADSCs-SVF: All
eligible patients will undergo lipoaspiration under gen-
eral anesthesia in a sterile surgical operating room set-
ting. 50 mL of blood in EDTA will be taken to prepare
platelet rich plasma (PRP). Approximately 100 - 500 gr
of adipose tissue will be isolated from the above proce-
dure performed by a plastic surgeon. Enzyme dissolution
procedure of the adipose tissue, using collagenase type I
solution under agitation for 2 hours plus 10 cc of
lecithine followed by two centrifugations at 100 g for 10
minutes the first and at 1800 g for 10 minutes the sec-
ond, will be performed to separate the stromal cell frac-
tion (pellet) from adipocytes. The pellets will be treated
with red lysis buffer. The final pellet will be re-sus-
pended and a small volume of suspension will be used
for flow cytometry analysis, counting CD29, CD73,
CD90, CD34, CD105, positive cells and CD14, CD31
and CD45 negative cells in Coulter Epics XL/MCL. 10
mL of the suspension will be used for bacterial check
with the BacT/Alert system (with colorimetric carbon
dioxide detector). In the case of an infected sample the
microorganism will be identified with VITEK 2 Compact
15 and will be excluded. A volume of DMSO solution
will be added in the remaining suspension so that the
final volume contains 10% DMSO and 2% Haes-steril
200. The cells will be cryo-preserved gradually and
stored in cryovials, air-tightly sealed with cryoflex mem-
brane. The vials will be placed in constant temperature
in liquid nitrogen and will be stored there. Viability of
the cells will be estimated by tryphan blue. A total of 3-
Patients’ screening
Patients’ enrolment
(UIP,Informconsent,FVC>50%,DLCO>35%)
Lipoaspiration
IsolationandactivationofADSCs
RandomizationbasedonlevelofTreatment
Labelingwith99mTcͲHMPAO
EndobronchialInfusion
Scintigraphic analysis
HospitalizationexamsͲPatient’sshortͲtermfollowͲup
Patient’slongͲtermfollowup
(FVC,DLCO,6MWT,ABGs,MRC,SGRQ,CAT, HRCT,wholebodyCTscan)
Figure 1 Step-up procedure of protocol proposal of the
endobronchial infusion of ADSCs in patients with IPF starting
with patients’ screening and enrolment and ending with
follow-up period. Abbreviations: 6MWT: 6-minute walking test,
ABGs: Arterial blood gases, ADSCs: Adipose-derived stem cells, CAT:
Cough Assessment Test, DLCO: Diffuse Lung Capacity for carbon
monoxide FVC: Forced Vital Capacity, HRCT: High Resolution
Computed Tomography, MRC: Medical Research Council- SGRQ:
Saint George’s Research Questionnaire, UIP: Usual Interstitial
Pneumonia (histologic or radiologic)
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6 cells per gram of adipose tissue is expected to
be isolated. Based on the current literature [29], since
SVF represents an heterogeneous cell population it is
anticipated that approximately 50-70% of the total num-
ber of isolated cells to be of mesenchymal origin mean-
ing CD29, CD105, CD90, CD73 positive and CD34,
CD45 negative cells and 20-30% mature endothelial
(CD31 and positive) and hematopoetic (CD34 positive)
cells.
5) Activation of ADSCs- SVF: ADSCs- SVF though
large in number lie dormant within the adipose tissue
and therefore they require activation to come into full
functionality for more successful implantation into the
host tissue and to begin self-renewal by cell division and
formation of other cell types by differentiation and
transdifferentiation. In order to increase the anti-inflam-
matory, angiogenic, anti-apoptotic and perhaps regen-
e r a t i v ep o t e n t i a lo fA D S C sw ew i l la p p l yat w o - s t e p
activation procedure: a) Activation through autologous
PRP. Isolated SVF cells will be subjected to full activa-
tion using autologous PRP derived from 50 ml of per-
ipheral blood drawn from each patient. PRP as a storage
vehicle of growth factors, is a new application of tissue
engineering which was considered for the application of
growth factors. PRP is a concentration of platelets in
plasma developed by gradient density centrifugation. It
contains many growth factors, such as vascular endothe-
lial growth factor (VEGF), epidermal growth factor
(EGF), insulin-like growth factor (IGF), Keratinocyte
growth factor (KGF), hepatocyte growth factor (HGF)
and stromal derived factor (SDF), that may potentially
accelerate proliferation of stem cells, improve their che-
motactic activity and facilitate their engraftment to the
multilayer vessels in order to exert their beneficial prop-
erties. b) Activation using low level laser irradiation (5 J/
cm
2). The syringe containing isolated SVF cells enriched
with PRP solution will be placed a laser device specifi-
cally manufactured for the purposes of this study by
Adistem Ltd. Photobiostimulation has been proposed to
exert several biological actions including upregulation of
angiogenic (VEGF) and anti-inflammatory (IL-1 receptor
antagonists, SDF) mediators as well as down-regulation
of inflammatory cytokines including tumor necrosis fac-
tor(TNF)- alpha, IL-1, 6 and 8 and reactive oxygen spe-
cies [30] (Figure 1).
6) Randomization of patients depending on the
level of treatment: To define and standardize the opti-
mal dose regimen that will be both safe and effective we
will randomize our 12 patients in the phase I trial into
two categories depending on the level of treatment,
meaning the number of SVF cells infused per broncho-
scopy. In particular we will define as low treatment level
the infusion of 0.5 × 10
6 SVF cells per kgr of body
weight per infusion meaning a total of 1.5 × 10
6 SVF
cells per kgr of body weight (approximately 120 × 10
6
cells in total) and as high treatment level the infusion of
1×1 0
6 of SVF cells per kgr of body weight per infusion
meaning a total of 3 × 10
6 SVF cells per kgr of body
weight (approximately 240 × 10
6 cells in total). The
dose regimen will be based on data arising from pre-
vious published studies in patients suffering from myo-
cardial infarction where a dose escalation procedure was
applied using a single infusion of 0.5, 1.6 and 5 millions
bone marrow mesenchymal stem cells (BM-MSCs) per
body weight. Results from the former study demon-
strated the absence of a dose-dependent effect while no
differences in side-effects between the three studied
groups were observed [20]. Moreover, an ongoing clini-
cal trial (the TIME study), with a registration number of
NCT00684021, is studying the safety and efficacy of one
single dose of intravenously infused 150 million cells in
total (meaning 0.5 million cells per kgr of body weight)
in patients who had experienced a heart attack. Finally,
a recent ongoing clinical trial by Matthay et al [31]. is
estimating the safety of two single dose regimens of 5
and 10 million BM -MSCs per kgr of body weight in
patients with acute lung injury. Patients in the two ran-
domization groups will be age, sex and disease severity
(based on spirometry and HRCT criteria) matched. Our
study dose-escalating regimen is in accordance with the
existing safety data arising from both published and cur-
rently ongoing clinical trials (Figure 1).
7) Labeling of ADSCs with
99 mTc-HMPAO
(
99 mTc-ceretec): To visualize ADSCs within the lung,
in a representative number of patients (n = 4), we will
label them with
99 mTc-HMPAO (
99 mTc-ceretec)
according to a modified protocol [32]. A fraction of
isolated ADSCs will be diluted into a 5 cc syringe with
sodium chloride 0.9% and incubated with a vial con-
taining 0.5 mg of ceretec reconstituted with approxi-
mately 2.0 mCi of free technetium (
99 mTcO4
-)a n d
prepared to be infused within the right lung. A second
syringe containing unlabeled ADSCs and 5 mL sodium
chloride 0.9% reconstituted with approximately 2.0mCi
99 mTcO4
- a n dp r e p a r e dt ob ea d m i n i s t e r e di n t ot h e
left lung serving as control sample. As depicted in Fig-
ure 2 and as was expected, signal intensity was much
stronger in the right lung and this effect remained
even 24 hours after the infusion, indicating the pre-
s e n c eo fA D S C s( F i g u r e1 ) .
8) Endobronchial Infusion: The patient will then
u n d e r g ob r o n c h o s c o p yu s i n gaf l e x i b l eb r o n c h o s c o p e ,
under local anesthesia (xylocaine). The flexible broncho-
scope will be guided into the lower lobes of both lungs
and 1 aliquot of 10 cc SVF cells will be infused using a
small catheter (2.0 mm of diameter) through the
bronchoscopic channel. Procedure will be repeated
thrice at monthly intervals (Figure 1).
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Page 4 of 99) Scintigraphic analysis: Planar imaging of the lungs
in anterior and posterior position will be performed 30
min, 90 min and 24 hours after the administration. At
24 hours single photon emission tomography (SPECT)
imaging of the lungs will be also done. Imaging will be
implemented in a single-head gamma-camera (GE Mil-
lennium MPS, Milwaukee USA) equipped with a low
energy high resolution (LEHR) parallel-hole collimator.
For planar imaging the matrix size will be set at 256 ×
256, while for SPECT at 128 × 128 pixels; the photopeak
will be centered at 140 keV, with a symmetrical 20%
window. The tomographic imaging parameters consisted
of a 360°-rotation angle, a circular technique and an
acquisition time of 30 sec per frame. Raw imaging data
will be reconstructed using the Butterworth-filtered
back-projection algorithm, generating tomographic
views of the lungs in the 3 planes (transverse, coronal,
and sagittal). In order to estimate the retention of the
radiolabeled cells in the lung in comparison to free tech-
netium we will draw regions of interest (ROI’s) over the
right and left lung in the posterior images at 30, 90 min
and 24 hours (Figure 2).
10) Patient’sd i s c h a r g e :The patient will be dis-
charged 24 hours post-bronchoscopy given that he/she
is afebrile and hemodynamically stable, with no signs of
infection or any type of allergic reaction.
11) Clinical, functional and radiological assess-
ment: Arterial blood gases (ABGs) coupled with clinical
A
D C
B
E F
Figure 2 99mTc lung scintigraphy at different time points (30 min, 90 min and 24 hours) after endobronchial infusion of adipose
derived mesenchymal stem cells (ADmSCs). Retention of radiolabeled cells (99mTc-HMPAO) (right lung-RT) in comparison to cells with free
99mTcO4 (without ceretec-HMPAO) (left lung-LT) was estimated with computerized image analysis by drawing regions of interest (roi) and
calculating the average counts/pixels (aver.count). As depicted in panels A (anterior view) and B (posterior view), signal intensity was significantly
stronger in the right lung compared to left lung (roi 334.65 vs. 93.69, respectively), 30 minutes after endobronchial infusion of ADmSCs and this
difference remained 90 minutes (panels C and D) (roi 227.24 vs. 37.89, respectively), as well as 24 hours (panels E and F) (roi 14.76 vs. 1.22,
respectively) after the infusion, indicating the presence of radiolabeled ADmSCs (99mTc-HMPAO). On the contrary, ADmSCs instilled within the
left lung were reconstituted only with free technetium (
99 mTcO4
-) without ceretec-HMPAO and therefore produced minimal signal intensity
within the lung. Free technetium uptake by the stomach is a normal finding due to the presence of free pertechnetate.
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scales), health-related quality of life (Saint George’s
Research Questionnaire-SGRQ and cough assessment
test-CAT) and functional (6-minute walking test-MWT,
FVC and DLCO) assessment will be performed every
month after the first infusion until the end of the fol-
low-up period (12 months) and HRCT evaluation 6
months after the first infusion in order to estimate any
potential clinical, functional and radiological differences
compared to baseline modalities (Table 1).
Primary end-points (Safety and Toxicity levels)
The procedure is safe and well tolerated by the
patients, as reflected by the absence of signs compati-
ble with infection, allergic reaction, disease acute
exacerbation, and ectopic tissue formation, at 12
months after the first post-endobronchial infusion of
SVF cells (total follow-up duration for each patients =
12 months).
In particular, patients will be subdivided into three
categories depending on the level of toxicity, defined as:
1) Low level, including minor side effects such as
increased cough, low fever (less than 37.5°C, skin
allergic reactions)
2) Medium level, including non-life threatening
allergic reactions, infections that do not require hos-
pitalization, elevation of liver enzymes or creatinine
serum levels.
3) High level, including death and/or life threaten-
ing major adverse events such as disease acute
exacerbations defined as follows:
a) If the patient experiences a significant worsen-
ing of dyspnea and a decline in exercise toler-
ance associated with a 10% decrement of their
F V C ,a1 0m m H gc h a n g ei nP a O 2 or 50%
increase in their oxygen requirement, and a sig-
nificant progression in their radiographic score
between the three month clinic visits;
b) If the patient needs to be admitted to the hos-
pital because of worsening respiratory failure
requiring mechanical ventilation, worsening gas
exchange, or presumed pulmonary infection.
c) If the patient develops ectopic tissue formation
compatible with carcinogenesis as assessed by
whole body computed tomography at 12 months
after the first post-endobronchial infusion of SVF
cells
Exploratory secondary end-points:
1) Assessment of Forced Vital Capacity (FVC%)
predicted.
2) Assessment of Diffuse Lung Capacity for carbon
monoxide (DLCO%) predicted.
3) Assessment of 6MWT.
4) Assessment of dyspnea scales (Borg, MRC) as well
as health-related quality of life questionnaires (SGRQ)
5) Assessment of the disease extent and severity as
reflected by chest high resolution computed tomography
(HRCT) at 6 and 12 months post-bronchoscopy.
*HRCT (scoring grade 0 = no lesion, grade 1 = less
than 5% of the lobe, grade 2: 6-25% of the lobe,
grade 3: 26-50% of the lobe, grade 4 = 51-75% of the
lobe, grade 5 = 76-100% of the lobe). The “ground-
glass” alveolitis will be defined as increased opacifi-
cation of the lung without obscuration of the bron-
chial and vascular markings, whereas the fibrosis
score will include thickening of the alveolar septa
and subpleural areas of honeycombing.
Statistical analysis
Statistical analysis will be performed using the SPSS 16.0
software. Safety and exploratory efficacy secondary end-
points will be observed for each patient against the base-
line values. A p value < 0.05 will be considered as statis-
tically significant.
Table 1 Scheduled visits following endobronchial infusion of ADScs
No of
Visit
Time-
point
(days)
ADSCs
infusion
Physical
Examination
Routine Laboratory
tests
MRC dyspnea
scale
SGRQ
+
CAT
6MWT PFTs ABGs HRCT
10 1
st XX X X X X X X
23 0 2
nd XX X X X X X
36 0 3
rd XX X X X X X
49 0 X X X X X X X
5 180 X X X X X X X X
6 270 X X X X X X X
7 360 X X X X X X X X + whole body
HRCT scan
Abbreviations: 6MWT: 6-minute walking test, ABGs: Arterial blood gases, ADSCs: Adipose-derived stem cells, CAT: Cough Assessment Test, HRCT: High Resolution
Computed Tomography, PFTs: Pulmonary Function Tests, SGRQ: Saint George’s Research Questionnaire.
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The study will be performed in accordance with Institu-
tional Review Board and the Ethics and Scientific Com-
mittee of the University Hospital of Alexandroupolis,
Democritus University of Thrace standards. Original
protocol has already been approved by the Local Ethics
and Scientific Committee of the University Hospital of
Alexandroupolis, Democritus University of Thrace,
Greece (reference number EHD33/1SC/16-02-2010)
Study Duration & Termination
The clinical part of the study will start after the
approval of the responsible Ethics Committee and the
study initiation visit is performed.
The time frame of the study will be as follows:
￿ Total Clinical Duration: 24 months
￿ Recruitment Period of Phase Ib (12 subjects): 12
months
￿ Treatment + follow-up (per subject): 12 months
The entire study may be prematurely terminated/dis-
continued if there is:
1. Comprehensive deficiency in the recorded data or
protocol compliance so that the study cannot be reliably
assessed
2. Occurrence of undesired experiences or adverse
events necessitating termination (high toxicity level).
3. The Principal Investigator and the Project Manager
commonly decide premature termination, after consulta-
tion with the Ethics Committee.
In the event of early termination, Investigator will
cease use of the investigational drug immediately. A
written statement fully documenting the reasons for
such a termination will be provided from the Depart-
ment of Pneumonology, Democritus University of
Thrace to the Institutional Review Boards/Independent
Ethics and Scientific Commitees and Regulatory Autho-
rities of the University Hospital of Alexandroupolis,
Democritus University of Thrace, Greece.
Completed
The subject completes the study as per protocol at 12
months follow up after the first infusion of SVF cells
and a whole-body CT scan will be performed at the end
of the follow-up period to estimate the presence or not
of ectopic tissue formation.
Discontinued/withdrawn
Withdrawal from the study can occur under the follow-
ing circumstances:
1. Death
2. Intolerable toxicity during infusion of test drug
3. Subject consent withdrawal
4. Investigator’s discretion
5. Screening errors: From an analysis perspective, a
‘screening error’ is any subject who was enrolled into
the study, e.g. was attributed a CRF with subject num-
ber, but was withdrawn (before or after randomization)
prior to administration of IP for reasons such as proto-
col violation (inclusion/exclusion criteria) or withdrawal
of consent.
Recording Subject Withdrawals
In the event of a subject withdrawal, the following infor-
mation must be recorded in the Case Report Form
(CRF):
1. Date of withdrawal
2. Reason for terminating participation in the study
3. Last treatment date
4. Follow-up assessments
The Investigator should continue to follow-up all ser-
ious adverse events or other adverse events that are con-
sidered to be related to the study drug, until they are
resolved or assessed to be chronic or stable by the
Investigator. This should be documented in the subject’s
medical records. This follow-up may be extended
beyond the end of the study period.
Replacement of Subjects Withdrawn
Subjects who are prematurely withdrawn from the study
will not be replaced.
Discussion
Currently, the application status of MSCs as treatment
modalities in IPF is still in its infancy and remains
exploratory. Although a number of safety and efficacy
clinical trials of MSCs as therapeutic options in
immune-mediated and cardiac diseases have already
been published with tantalizing results, to our disap-
pointment, pulmonary and critical care medicine have
traditionally lagged behind other therapeutic and
research fields including hematology, gastroenterology
and cardiology in translational studies of the use of
reparative cells [21-23,33,34]. Standing in front the
dilemma something or nothing the agony and at the
same time desire of chest physicians to test novel thera-
peutic options for patients with IPF is clearly under-
standable. MSCs and especially ADSCs may provide an
ethically uncontested, cost-effective, easily accessible and
well tolerated therapeutic option in the hands of chest
physicians in the following years. For these cell-based
therapies to become truly evolutionary there is only one
approach: phase I safety clinical trials followed by large
multicenter randomized controlled efficacy clinical trials
[21].
Nevertheless safety concerns mainly arising from IPF
pathogenesis that is still elusive and controversial
coupled with issues reflecting the origin and the
Tzouvelekis et al. Journal of Translational Medicine 2011, 9:182
http://www.translational-medicine.com/content/9/1/182
Page 7 of 9minimal potential of ADSCs to differentiate into fibro-
blastic colony forming units have severely hampered
clinicians’ efforts to apply, so far, cell-based therapies
for the treatment of this fatal disease [35,36].
To address the above concerns and to establish a rigid
basis for future efficacy clinical trials we propose for the
first time in the therapeutic field of IPF a protocol refer-
ring to a phase Ib nonrandomized clinical trial to evalu-
ate safety and feasibility of endobronchial infusion of
autologous ADSCs-SVF in patients with IPF of mild to
moderate disease severity. Original protocol has already
been approved by the Local Ethics and Scientific Com-
mittee of the University Hospital of Alexandroupolis,
Democritus University of Thrace, Greece (reference
number EHD33/1SC/16-02-2010) with the title “Ap r o -
spective, unicentric, non randomized, phase I clinical
trial to study the safety of the adipose-derived adult
stromal vascular fraction cells as a therapeutic agent in
Idiopathic Pulmonary Fibrosis”.
S of a rp r e l i m i n a r yd a t ar e c e n t l yp r e s e n t e da tt h e2 1
ST
European Respiratory Society Congress, Amsterdam
2011 in the form of an abstract seem promising and
intriguing since none of the 12 patients enrolled in the
study experienced any clinically significant cases of
infections, allergic reactions, acute exacerbations or
other major side effects requiring hospitalization. In
addition 6 months follow-up data revealed a marginal
improvement at 6MWD and FVC levels [21,37].
The main purpose of this project and consequently
this trial is to provide worldwide scientific committee
with pivotal safety data regarding this novel therapeutic
option and accelerate its application to a larger cohort
of patients in the context of multicenter phase II and III
clinical trials. There is plenty of room for further techni-
cal improvements, development and widespread accep-
tance and accessibility. However, pilot safety studies are
of major importance and represent the first hamper that
should be overcome to establish a rigid basis for larger
clinical trials where safety concerns will be addressed
cautiously and thoroughly and efficacy outcomes of high
scientific rigidity will be safely extracted.
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